Arkolith/Insider Trading/XENE/Form 4

Patou Gary

DirectorXenon Pharmaceuticals Inc. (XENE) · full profile →Form 4 · filed Jun 9, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$70K
Net Open-Market Flow
-$70K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 5, 2026Sell(S)1K$53.14$70K25K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-262672) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML